Soligenix announces USAN approved “hypericin sodium” as name for new ingredient

Soligenix announced that the United States Adopted Names, or USAN, Council has approved the use of the nonproprietary name of "hypericin sodium" for the novel active ingredient in both HyBryte for the treatment of cutaneous T-cell lymphoma, or CTCL, and SGX302 for the treatment of mild-to-moderate psoriasis. Information on hypericin sodium will be posted on the USAN website before the end of 2023 and will be submitted to the U.S. Pharmacopeial Convention for publication in the U.S. Pharmacopeia Dictionary of USAN and International Drug Names.